Description: SynCore Biotechnology Co.,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, and dermatology primarily in Taiwan. The company offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts; and distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases. It is also involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer;SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer;SB04 that is in Phase II clinical trials for the treatment of patients with dry age-related macular degeneration and SB05, a composition of cytostatic drug paclitaxel combined with neutral and positive lipids, which is in Phase III clinical trials for the treatment of patients with triple negative breast cancer and pancreatic cancer. The company has partnerships with Medigene AG; MacuCLEAR Inc.; Y-YBAR; Epipole Ltd.; Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes. The company was incorporated in 2008 and is headquartered in Yilan City, Taiwan. SynCore Biotechnology Co.,Ltd is a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Home Page: www.syncorebio.com
84 Chung Shan Road
Yilan City,
269
Taiwan
Phone:
886 3 958 6101
Officers
| Name | Title |
|---|---|
| Mr. Chih-Wen Lee | Founder & Chairman |
| Dr. Muh-Hwan Su | Pres & GM |
| Mr. Wen-Hsin Huang | VP & Head of Drug Devel. Department |
| Dr. Charn-Jung Chang | VP & Director of Ophthalmology |
| Mr. Hui-Hung Wang M.B.A. | VP & Director of Anticancer Drugs |
| Ms. Fern-Fang Lin | VP & Director of EndoTAG Clinical Devel. |
| Mr. Chia-Hao Liang | Head of Financial & Gen. Affairs Department and Accounting Mang. |
| Mr. Ruey-Wen Lin | Head of Quality Assurance Department |
Exchange: TWO
Country: TW
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.3444 |
| Price-to-Sales TTM: | 221.5779 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 65 |